Magainin, Rhône-Poulenc Rorer deal

MAGN and Fisons, which is now owned by RPR, decided not to conclude a definitive agreement to develop MAGN's MSI-843 magainin compound, which is in advanced preclinical development for the treatment of resistant pseudomonas infection in cystic fibrosis patients.

"We believe that MSI-843 has merit as a product opportunity," said RPR Executive Vice President Timothy Rothwell. "Unfortunately the merger of RPR and Fisons necessitates focusing on later-stage clinical opportunities." ...